Xiaoqiu Liu
University of California, San Diego
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Xiaoqiu Liu.
Molecular Pharmacology | 2006
Xiaoqiu Liu; Shu Qiang Sun; Aviv I. Hassid; Rennolds S. Ostrom
Cardiac fibroblasts produce and degrade extracellular matrix and are critical in regulating cardiac remodeling and hypertrophy. Cytokines such as transforming growth factor-β (TGF-β) play a fundamental role in the development of tissue fibrosis by stimulating matrix deposition and other profibrotic responses, but less is known about pathways that might inhibit fibrosis. Increased cAMP formation inhibits myofibroblast differentiation and collagen production by cardiac fibroblasts, but the mechanism of this inhibition is not known. We sought to characterize the signaling pathways by which cAMP-elevating agents alter collagen expression and myofibroblast differentiation. Treatment with 10 μM forskolin or isoproterenol increased cAMP production and cAMP response element binding protein (CREB) phosphorylation in cardiac fibroblasts and inhibited serum- or TGF-β-stimulated collagen synthesis by 37% or more. These same cAMP-elevating agents blunted TGF-β-stimulated expression of collagen I, collagen III, and α-smooth muscle actin. Forskolin or isoproterenol treatment blocked the activation of extracellular signal-regulated kinase 1/2 (ERK1/2) induced by TGF-β despite the fact that these cAMP-elevating agents stimulated ERK1/2 activation on their own. cAMP-elevating agents also attenuated the activation of c-Jun NH2-terminal kinase and reduced binding of the transcriptional coactivator CREB-binding protein 1 to transcriptional complexes containing Smad2, Smad3, and Smad4. Pharmacological inhibition of ERK completely blocked TGF-β-stimulated collagen gene expression, but expression of an active mutant of MEK was additive with TGF-β treatment. Thus, cAMP-elevating agents inhibit the profibrotic effects of TGF-β in cardiac fibroblasts largely through inhibiting ERK1/2 phosphorylation but also by reducing Smad-mediated recruitment of transcriptional coactivators.
Laboratory Investigation | 2017
Xiaoqiu Liu; Simon S. Wong; Carmen A. Taype; Jeeyeon Kim; Tzu-Pin Shentu; Celia Espinoza; J. Cameron Finley; John E. Bradley; Brian P. Head; Hemal H. Patel; Emma J. Mah; James S. Hagood
Thy-1-negative lung fibroblasts are resistant to apoptosis. The mechanisms governing this process and its relevance to fibrotic remodeling remain poorly understood. By using either sorted or transfected lung fibroblasts, we found that Thy-1 expression is associated with downregulation of anti-apoptotic molecules Bcl-2 and Bcl-xL, as well as increased levels of cleaved caspase-9. Addition of rhFasL and staurosporine, well-known apoptosis inducers, caused significantly increased cleaved caspase-3, -8, and PARP in Thy-1-transfected cells. Furthermore, rhFasL induced Fas translocation into lipid rafts and its colocalization with Thy-1. These in vitro results indicate that Thy-1, in a manner dependent upon its glycophosphatidylinositol anchor and lipid raft localization, regulates apoptosis in lung fibroblasts via Fas-, Bcl-, and caspase-dependent pathways. In vivo, Thy-1 deficient (Thy1−/−) mice displayed persistence of myofibroblasts in the resolution phase of bleomycin-induced fibrosis, associated with accumulation of collagen and failure of lung fibrosis resolution. Apoptosis of myofibroblasts is decreased in Thy1−/− mice in the resolution phase. Collectively, these findings provide new evidence regarding the role and mechanisms of Thy-1 in initiating myofibroblast apoptosis that heralds the termination of the reparative response to bleomycin-induced lung injury. Understanding the mechanisms regulating fibroblast survival/apoptosis should lead to novel therapeutic interventions for lung fibrosis.
Molecular Pharmacology | 2002
Rennolds S. Ostrom; Xiaoqiu Liu; Brian P. Head; Caroline Gregorian; Tammy M. Seasholtz; Paul A. Insel
American Journal of Physiology-cell Physiology | 2004
Xiaoqiu Liu; Rennolds S. Ostrom; Paul A. Insel
Journal of Pharmacology and Experimental Therapeutics | 2005
Xiaoqiu Liu; Shu Qiang Sun; Rennolds S. Ostrom
american thoracic society international conference | 2012
Xiaoqiu Liu; Head P. Brian; John E. Bradley; J. C. Finley; Emma J. Mah; Hemal H. Patel; James S. Hagood
american thoracic society international conference | 2011
Xiaoqiu Liu; James S. Hagood
american thoracic society international conference | 2011
Xiaoqiu Liu; James S. Hagood
The FASEB Journal | 2008
Xiaoqiu Liu; Fengying Li; Rennolds S. Ostrom
Archive | 2008
Muthusamy Thangavel; Xiaoqiu Liu; Rennolds S. Ostrom